IMR Press / FBL / Volume 8 / Issue 6 / DOI: 10.2741/965

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
The treatment of allergic bronchopulmonary aspergillosis
Show Less
1 Dept of Pediatrics and Medicine (Allergy), 9000 W. Wisconsin Ave., Suite 411, Milwaukee, WI 53226, USA

Academic Editor: Viswanath Kurup

Front. Biosci. (Landmark Ed) 2003, 8(6), 243–245;
Published: 1 May 2003
(This article belongs to the Special Issue Allergic aspergillosis)

Allergic bronchopulmonary aspergillosis (ABPA) is a disease characterized by asthma, peripheral eosinophilia, pulmonary infiltrates, hypersensitivity to Aspergillus fumigatus and bronchiectasis. The treatment of ABPA depends on the stage of the disease, and includes following clinical symptoms, serum IgE levels, pulmonary function tests, and chest radiographs. This review covers the current treatment options for ABPA.

Back to top